Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib

Abstract

Targeted therapy is commonly used for treating advanced malignant tumors. Compared with cytotoxic drugs, targeted drugs have the characteristics of good curative results, less adverse effects, and convenient oral administration. Hence, they are especially suitable for patients with cancer who are not able to tolerate chemotherapy. Anti-angiogenic therapy can achieve the objective by inhibiting the formation of new blood vessels in tumors. Apatinib is a novel tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2. It has been proven to be effective and safe in treating patients with gastric carcinoma and gastroesophageal junction carcinoma. So far, no reports are available on the treatment of esophageal cancer with apatinib. Two patients with advanced esophageal cancer were treated with oral apatinib because of their poor physical condition. After treatment, the dyspnea symptoms disappeared and quality of life significantly improved. Chest computed tomography showed massive necrosis of tumor tissues in each patient. The tumors significantly reduced and a cavity was formed locally in each patient. However, both patients died of massive hemoptysis, probably due to the rupture of the bronchial artery eroded by tumors. The results indicated that apatinib was effective in treating some patients with advanced esophageal cancer, and adverse effects were controllable. However, doctors should choose appropriate candidates according to apatinib’s indications. In addition, the use of apatinib should be carefully controlled for patients with esophageal cancer, especially in those with large vessels and trachea or bronchus eroded by tumor, so as to avoid or reduce the occurrence of fatal hemorrhage.

<p>Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study</p>

“…Angiogenesis is closely related to tumor growth, proliferation and metastasis, thus angiogenesis is generally considered an attractive target in NSCLC therapy. [15][16][17] At the same time, because of the benefits of immunotherapy for…”

Merkel cell carcinoma of the thigh: case report and review of the literature

“…However, these symptoms were significantly relieved quickly when they took apatinib. At the same time, their diseases were controlled for a certain time, which may demonstrate that apatinib is effective for some patients with esophageal cancer 39. In view of the clinical effectiveness of endostar and apatinib and the vascular correlation of MCC, it may be an effective treatment to select antivascular drug therapy.…”

Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non‐small cell lung cancer after second‐line chemotherapy treatment: A retrospective study

“…Angiogenesis is closely related to tumor growth, proliferation, progression, and metastasis; it supplies necessary oxygen, growth factors, and nutrients. Thus, angiogenesis is generally considered an attractive target in cancer therapy . VEGF plays an important role in angiogenesis; VEGFRs are TKIs that are the key regulators of this process .…”

“…Thus, angiogenesis is generally considered an attractive target in cancer therapy. [38][39][40] VEGF plays an important role in angiogenesis;…”